Salvador Martín Algarra

Universidad de Navarra

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Alejandra Tomás‐Velázquez

SPAIN

View details

Mariano Ponz-Sarvise

Universidad de Navarra

SPAIN

View details

Maya Niethard

University of Greifswald

GERMANY

View details

Sara Lopez-Tarruella

ASSOCIATE PROFESSOR

Universidad Complutense de Madrid

SPAIN

View details

Cristina Puig Saus

Adj Assistant Professor

David Geffen School of Medicine at UCLA

UNITED STATES

View details

Véronique Françoise Calleja

Chief Scientific Officer

HackBio

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Salvador Martín Algarra

Research Interests

Explore related searches

Contact this professor

Articles (13)

Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study

Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.

Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosis

Erratum: Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma (Cancer Cell (2020) 38(4) (500–515.e3), (S1535610820304165), (10.1016/j.ccell.2020.08.005))

Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy,Calidad asistencial en España: gestión de náuseas y vómitos inducidos por quimioterapia alta y moderadamente emetógena

Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

Collaborators (6)

Alejandra Tomás‐Velázquez

Mariano Ponz-Sarvise

Maya Niethard

Sara Lopez-Tarruella

Cristina Puig Saus

Véronique Françoise Calleja

Make your next move.